PT3383397T - Composições farmacêuticas contendo doravirina, tenofovir disoproxil fumarato e lamivudina - Google Patents

Composições farmacêuticas contendo doravirina, tenofovir disoproxil fumarato e lamivudina

Info

Publication number
PT3383397T
PT3383397T PT168713329T PT16871332T PT3383397T PT 3383397 T PT3383397 T PT 3383397T PT 168713329 T PT168713329 T PT 168713329T PT 16871332 T PT16871332 T PT 16871332T PT 3383397 T PT3383397 T PT 3383397T
Authority
PT
Portugal
Prior art keywords
doravirine
lamivudine
pharmaceutical compositions
compositions containing
tenofovir disoproxil
Prior art date
Application number
PT168713329T
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58797976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3383397(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PT3383397T publication Critical patent/PT3383397T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT168713329T 2015-12-02 2016-11-29 Composições farmacêuticas contendo doravirina, tenofovir disoproxil fumarato e lamivudina PT3383397T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562261953P 2015-12-02 2015-12-02

Publications (1)

Publication Number Publication Date
PT3383397T true PT3383397T (pt) 2021-11-03

Family

ID=58797976

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168713329T PT3383397T (pt) 2015-12-02 2016-11-29 Composições farmacêuticas contendo doravirina, tenofovir disoproxil fumarato e lamivudina

Country Status (21)

Country Link
US (2) US10603282B2 (pt)
EP (2) EP3383397B1 (pt)
JP (1) JP6866374B2 (pt)
KR (1) KR20180081082A (pt)
CN (1) CN108367008B (pt)
AU (1) AU2016361612B2 (pt)
BR (1) BR112018011085B1 (pt)
CA (1) CA3006192C (pt)
CY (1) CY1124748T1 (pt)
DK (1) DK3383397T3 (pt)
ES (1) ES2895951T3 (pt)
HR (1) HRP20211687T1 (pt)
HU (1) HUE056978T2 (pt)
LT (1) LT3383397T (pt)
MX (1) MX2018006773A (pt)
PL (1) PL3383397T3 (pt)
PT (1) PT3383397T (pt)
RS (1) RS62466B1 (pt)
RU (1) RU2736941C2 (pt)
SI (1) SI3383397T1 (pt)
WO (1) WO2017095761A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895951T3 (es) * 2015-12-02 2022-02-23 Merck Sharp & Dohme Composiciones farmacéuticas que contienen doravirina, fumarato de tenofovir disoproxil y lamivudina
EP3612226A1 (en) * 2017-04-18 2020-02-26 Cipla Limited Combination therapy for use in treating retroviral infections
MX2020008076A (es) * 2018-02-02 2020-09-24 Genentech Inc Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
CN113288905A (zh) * 2021-07-14 2021-08-24 石家庄龙泽制药股份有限公司 含多替拉韦钠、拉米夫定和富马酸诺福韦酯的药物组合物
CN115554248B (zh) * 2022-08-25 2023-09-22 平阳润德医院有限公司 一种治疗小儿巨细胞病毒感染性肝炎的肠溶型中药制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
ATE474560T1 (de) 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
WO2008156632A1 (en) * 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
EP2295038B1 (en) 2009-09-11 2013-05-29 AiCuris GmbH & Co. KG Solid dispersion comprising an anti-HIV agent
MX2012011379A (es) 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
AU2012264475A1 (en) 2011-05-30 2013-10-31 Cipla Limited Pharmaceutical antiretroviral composition
WO2014130553A2 (en) 2013-02-20 2014-08-28 Abbvie Inc. Tablet dosage forms
KR102601617B1 (ko) 2013-11-22 2023-11-10 머크 샤프 앤드 돔 엘엘씨 비-뉴클레오시드 역전사 효소 억제제의 조성물
WO2015179448A1 (en) * 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
ES2895951T3 (es) * 2015-12-02 2022-02-23 Merck Sharp & Dohme Composiciones farmacéuticas que contienen doravirina, fumarato de tenofovir disoproxil y lamivudina

Also Published As

Publication number Publication date
RU2018123620A3 (pt) 2020-03-26
JP2018535991A (ja) 2018-12-06
EP3383397A1 (en) 2018-10-10
CA3006192A1 (en) 2017-06-08
EP3383397B1 (en) 2021-09-22
RU2018123620A (ru) 2020-01-09
BR112018011085A2 (pt) 2018-11-21
SI3383397T1 (sl) 2021-12-31
EP3960163A1 (en) 2022-03-02
US20190254977A1 (en) 2019-08-22
US20200179291A1 (en) 2020-06-11
WO2017095761A1 (en) 2017-06-08
CN108367008A (zh) 2018-08-03
CY1124748T1 (el) 2022-07-22
AU2016361612B2 (en) 2021-07-29
US10842751B2 (en) 2020-11-24
EP3383397A4 (en) 2019-08-07
US10603282B2 (en) 2020-03-31
KR20180081082A (ko) 2018-07-13
LT3383397T (lt) 2021-11-25
JP6866374B2 (ja) 2021-04-28
CN108367008B (zh) 2021-04-30
DK3383397T3 (da) 2021-11-08
AU2016361612A1 (en) 2018-05-17
RU2736941C2 (ru) 2020-11-23
PL3383397T3 (pl) 2021-12-27
HUE056978T2 (hu) 2022-04-28
HRP20211687T1 (hr) 2022-03-04
RS62466B1 (sr) 2021-11-30
BR112018011085B1 (pt) 2020-06-02
MX2018006773A (es) 2018-08-01
ES2895951T3 (es) 2022-02-23
CA3006192C (en) 2023-11-28

Similar Documents

Publication Publication Date Title
IL265360B (en) Pharmaceutical composition
HK1248547A1 (zh) 包含替諾福韋和恩曲他濱的藥物製劑
IL265260B (en) pharmaceutical preparations
HK1254343A1 (zh) 藥物製劑
ZA201903101B (en) Pharmaceutical formulations
IL262654A (en) Pharmacy preparation
PT3383397T (pt) Composições farmacêuticas contendo doravirina, tenofovir disoproxil fumarato e lamivudina
IL265349A (en) Pharmaceutical composition
PT3278801T (pt) Composição farmacêutica que contém mirabegron
IL263040A (en) Pharmaceutical composition comprising eteplirsen
HUE044889T2 (hu) Gyógyászati készítmények
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
IL265428A (en) Pharmaceutical composition
PT3476391T (pt) Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq
GB201620519D0 (en) Pharmaceutical composition
GB201620517D0 (en) Pharmaceutical composition
GB201620515D0 (en) Pharmaceutical composition
GB201620513D0 (en) Pharmaceutical composition
GB201620516D0 (en) Pharmaceutical composition
GB201616093D0 (en) Pharmaceutical composition